Chimerix Announces Pricing of Public Offering of Common Stock
20 janv. 2021 20h03 HE
|
Chimerix, Inc.
DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock
19 janv. 2021 16h19 HE
|
Chimerix, Inc.
DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
08 janv. 2021 06h00 HE
|
Chimerix, Inc.
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential...
Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference
06 janv. 2021 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
07 déc. 2020 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
05 nov. 2020 16h01 HE
|
Chimerix, Inc.
DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update
05 nov. 2020 07h00 HE
|
Chimerix, Inc.
– Completed Rolling NDA Submissions for Both BCV Tablet and Suspension Formulations as Medical Countermeasure for Smallpox – – First Patient Visit for DSTAT Phase 3 AML Study Expected in Early...
Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
29 oct. 2020 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Participate in Upcoming Investor Conferences
10 sept. 2020 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update
10 août 2020 07h00 HE
|
Chimerix, Inc.
– Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 – – Currently Enrolling Phase 2/3 Study of DSTAT in Patients with COVID-19; Phase 2 Enrollment Completion Expected in Fourth...